Advertisement
Advertisement
U.S. Markets open in 7 hrs 7 mins
Advertisement
Advertisement
Advertisement
Advertisement

BioVaxys Technology Corp. (BIOV.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1200+0.0250 (+26.32%)
At close: 03:34PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0950
Open0.0000
Bid0.1000 x N/A
Ask0.1200 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume68,420
Market Cap10.904M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0640
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    BIOVAXYS CLOSES FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

    BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of its previously announced non-brokered private placement (the "Private Placement"). Pursuant to the Final Tranche of the Private Placement, the Company has issued 1,350,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $135,000. Including the first tranche of the Private Placement which completed on August

  • CNW Group

    BioVaxys Announces New Chief Financial Officer

    BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in October 2020. Mr. McLeod will be resuming his full-time duties with Fehr & Associates CPA.

  • CNW Group

    BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study

    BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the Company's vaccine for SARS-CoV, which is being used in the collaboration with The Ohio State University ("OSU") to develop a pan-sarbecovirus vaccine. The next step is measuring neutralizing antibody development to s

Advertisement
Advertisement